Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation
Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation
sellas life sciences的可能的骨髓性白血病治療藥物獲得歐盟孤兒藥品認證
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。